Noticias de PFE_US

Mercado

Noticias del mercado

Últimas noticias sobre PFE_US — 665 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PFE_US ✕ 665 resultados
01/10/2026 PFE_US — Yahoo Finance
Pfizer Says Eczema Drug Shows Significant Skin Clearance

Pfizer Inc. (NYSE:PFE) on Thursday presented detailed Phase 2 results for tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. The ongoing trial met its primary endpoint, showing a statistically significant increase in participants achieving EASI-75 at Week 16 across all evaluated doses compared to placebo. Strong Efficacy Across Phase 2 Trial Stages The trial evaluated biologic-naïve adult patients across two distinct stages. Stage 1 tested subcutaneous tilrekimig at 45

01/10/2026 PFE_US — unn.ua
Florida files lawsuit against Pfizer over COVID-19 vaccine - Reuters

УНН Health ✎ Florida's attorney general accused Pfizer of misleading the public about the vaccine's safety and effectiveness. The state is seeking fines and the di…

01/10/2026 PFE_US — Seeking Alpha
Florida AG sues Pfizer over 'misconduct' related to COVID vaccine risks

Florida AG demanda a Pfizer, alegando marketing engañoso sobre la seguridad de la vacuna COVID-19 y riesgos ocultos. Lea más aquí.

01/10/2026 PFE_US — grafa.com
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results

Pfizer reported Phase 2 tilrekimig results showing improved EASI-75 responses in adults with moderate-to-severe atopic dermatitis.

01/10/2026 PFE_US — Seeking Alpha
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE)

Pfizer (PFE) says that more patients with atopic dermatitis who received its eczema drug tilrekimig had stronger skin clearance in a mid-stage trial. Read more here.

01/10/2026 PFE_US — Mugglehead Investment Magazine
Pfizer Inc details 61% EASI‑75 response in tilrekimig trial

Pfizer Inc. reported a 61% EASI-75 response on monthly tilrekimig versus 9.1% on placebo at Week 16 in a Phase 2 atopic dermatitis study.

01/10/2026 PFE_US — Yahoo Finance
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $28.1, moving 1.47% from the previous trading session.

30/09/2026 PFE_US — AD HOC NEWS
Pfizer stock after-hours at EUR 25.31: plus 0.04 percent versus prior close

Pfizer stock was at EUR 25.31 in after-hours trading at 9:41 p.m. CEST on September 30, 2026. It was

30/09/2026 PFE_US — AD HOC NEWS ES ← EN
Las acciones de Pfizer informan una orientación más alta para 2026 de 25,28 EUR

Pfizer stock reports higher 2026 guidance at EUR 25.28

30/09/2026 PFE_US — Stock Titan
With Pfizer's experimental drug, 62.5% in one group had eczema severity scores fall at least 75% by week 16.

Las tasas de EASI-75 estuvieron entre 38,7 y 51,9 puntos porcentuales por encima del placebo en las dosis de la Etapa 2; Pfizer ha comenzado la fase 3 de ensayos sobre eczema y asma.

30/09/2026 PFE_US — AD HOC NEWS
Pfizer stock pre-market at EUR 25.35: plus 0.20 percent

Pfizer stock is at EUR 25.35 pre-market, up 0.20 percent versus the prior Lang & Schwarz close. Pfiz

29/09/2026 PFE_US — AD HOC NEWS
Pfizer stock after-hours at EUR 25.25: minus 0.16 percent versus prior close

Las acciones de Pfizer cotizaban a 25,25 euros fuera de horario a las 8:53 p.m. CEST el 29 de septiembre de 2026, un descenso del 0,16 por ciento

29/09/2026 PFE_US — Bloomberg Law News ES ← EN
Carlyle gana disputa sobre plataforma de inteligencia artificial vinculada a Pfizer Covid Vax

Carlyle Wins Dispute Over AI Platform Linked to Pfizer Covid Vax

Página 21 de 34